Revance Therapeutics Prices Upsized Underwritten Public Offering Of 8 Mln Shares At $25.00/shr

Revance Therapeutics Inc. (RVNC) announced the pricing of an upsized underwritten public offering of 8 million shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 per share. All of the shares are being offered by Revance.

The company expects gross proceeds from the public offering to be $200.0 million, before deducting underwriting discounts and commissions and other offering expenses.

In addition, Revance has granted the underwriters a 30-day option to purchase up to an additional 1.20 million shares of its common stock at the public offering price, less underwriting discounts and commissions.

The public offering is expected to close on or about September 15, 2022.

The company plans to use the net proceeds from the offering to fund the commercialization of DAXXIFY, the RHA Collection of dermal fillers and OPUL, and for working capital, research and development and general corporate purposes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Foxconn, Apple Inc.'s key iPhone assembler, expects that its major plant in China, which is being hit hard by worker unrest following Covid-19 spread and related restrictions, would restart full production around late December to early January, Reuters reported citing a Foxconn source. Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165.
Follow RTT